4D Molecular Therapeutics Inc share price logo

4D Molecular Therapeutics Inc

NASDAQ: FDMT

Small Cap

$8.55

-0.09

(-1.04%)

Live

as on

4D Molecular Therapeutics Inc Stock Performance

as on June 9, 2026 at 2:37 am IST

  • Day's Low

    Day's High

    $8.41
    $8.81
    downward going graph

    1.64%

    Downside

    3.04%

    Upside

    downward going graph

  • 52 Week's Low

    52 Week's High

    $3.68
    $12.34
    downward going graph

    56.96%

    Downside

    44.33%

    Upside

    downward going graph

4D Molecular Therapeutics Inc share price movements today

Previous Close
$8.64
Open
$8.81
Volume
231.9K
Day's Low - High
$8.41 - $8.81
52 Week Low - High
$3.68 - $12.34

4D Molecular Therapeutics Inc Historical Returns

1 Month Return
-14.79 %
3 Month Return
+ 1.89 %
1 Year Return
+ 98.62 %
3 Year Return
-55.74 %
5 Year Return
-67.65 %

4D Molecular Therapeutics Inc Stock Fundamentals & Key Indicators

Check 4D Molecular Therapeutics Inc market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$451.7M

EPS (TTM)

-3.9196

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

0

PEG Ratio

0

EBITDA

-171.4M

Revenue (TTM)

88.2M

Profit Margin

-182.34%

Return On Equity TTM

-34.92%

4D Molecular Therapeutics Inc vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of 4D Molecular Therapeutics Inc with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %Dividend Yield %
4D Molecular Therapeutics Inc image
4D Molecular Therapeutics Inc
BUY$451.7M-67.65%NA-182.34%NA
Alnylam Pharmaceuticals Inc image
Alnylam Pharmaceuticals Inc
BUY$40.5B100.59%76.3312.55%NA
Vertex Pharmaceuticals Inc image
Vertex Pharmaceuticals Inc
BUY$113.4B111.64%26.5235.51%NA
Regeneron Pharmaceuticals Inc image
Regeneron Pharmaceuticals Inc
BUY$66.6B25.48%15.529.65%0.5700000000000001%

Stock Returns calculator for 4D Molecular Therapeutics Inc Stock including INR - Dollar returns

The 4D Molecular Therapeutics Inc stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

4D Molecular Therapeutics Inc investment value today

Current value as on today

₹2,19,581

Returns

₹1,19,581

(+119.58%)

Returns from 4D Molecular Therapeutics Inc Stock

₹96,552 (+96.55%)

Dollar Impact

₹23,029 (+23.03%)

Analyst Recommendation on 4D Molecular Therapeutics Inc Stock

Based on 17 analysts

BUY

94.12%

Buy

5.88%

Hold

0.00%

Sell

Based on 17 analysts, 94.12% of analysts recommend a 'BUY' rating for 4D Molecular Therapeutics Inc. Average target price of $28.22

4D Molecular Therapeutics Inc Share Price Target

Get share price movements and forecasts by analysts on 4D Molecular Therapeutics Inc.

What analysts predicted

69.7%UPSIDE

Target Price

$28.22

Current Price

$8.55

Analyzed by

17 Analysts

Target

$28.22

4D Molecular Therapeutics Inc target price $28.22, a slight upside of 69.7% compared to current price of $8.55. According to 17 analysts rating.

Indian Investors' Interest in 4D Molecular Therapeutics Inc Stock

Search interest for 4D Molecular Therapeutics Inc Stock has decreased by -31% in the last 30 days, reflecting a downward trend in search activity.

Time period: to

Change:-31% versus previous 30 day period

4D Molecular Therapeutics Inc Quarterly Profit & Loss

All numbers in Millions USD

Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Total Revenue
0
0
0
0
0
0
0
0
85
3
Gross Profit
-26
-27
-31
0
-1
0
-47
-47
83
0
Operating Income
-36
-38
-42
-51
-56
-53
-59
-61
14
-73
EBITDA
-35
-36
-41
-49
-61
-51
-58
-55
6
-71
Interest Expense
1
-
-
-
-
-
-
-
-
-
Depreciation
1
1
1
1
1
1
1
2
1
2
Income Before Tax
-32
-32
-34
-43
-49
-47
-54
-56
19
-68
Income Tax Expense
6
0
-
-
0
-
-
-
-
-
Net Income
-32
-32
-34
-43
-49
-47
-54
-56
19
-68
Net Profit Margin
169910.53%
-115717.86%
-699060.00%
-1461433.33%
-4967100.00%
-342657.14%
-364386.67%
-63195.56%
22.80%
-2256.65%

4D Molecular Therapeutics Inc Annual Profit & Loss

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Total Revenue
5
14
6
13
18
3
20
0
85
Gross Profit
-7
-4
-31
-39
18
3
-76
0
77
Operating Income
-11
-10
-50
-56
-71
-110
-112
-187
-159
EBITDA
-10
-9
-44
-55
-68
-106
-108
-181
-151
Interest Expense
-
-
-
0
3
6
-
-
-
Depreciation
0
0
1
1
3
3
5
6
7
Income Before Tax
-11
-9
-49
-56
-71
-107
-100
-160
-140
Income Tax Expense
0
0
3
0
-3
-6
5
-
-
Net Income
-11
-9
-49
-56
-68
-101
-100
-160
-140
Net Profit Margin
-193.83%
-67.59%
-705.78%
-416.49%
-378.63%
-3230.30%
-486.59%
-434778.38%
-164.43%

4D Molecular Therapeutics Inc Quarterly Cash Flow

All numbers in Millions USD

Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Net Income
-32
-34
-43
-49
-47
-54
-56
19
-68
Operating Cash Flow
-29
-30
-29
-45
-47
-43
-46
28
-68
Investing Cash Flow
-263
-73
27
7
31
-13
17
-128
68
Financing Cash Flow
318
17
0
0
-
0
0
111
11
Change in Cash
26
-86
-1
-38
-15
-63
-28
11
12

4D Molecular Therapeutics Inc Annual Cash Flow

All numbers in Millions USD

Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Net Income
-9
-49
-56
-71
-107
-100
-160
-140
Operating Cash Flow
-16
-36
-50
-69
-86
-75
-134
-109
Investing Cash Flow
0
-3
-1
-172
-17
115
-302
-92
Financing Cash Flow
84
-2
278
118
3
156
337
112
Change in Cash
67
-42
227
-123
-100
196
-99
-89

Global Institutional Holdings in 4D Molecular Therapeutics Inc

Funds
Holdings
Susquehanna International Group, LLP
0.26%
HHG PLC
10.04%
Trails Edge Capital Partners, LP
2.49%
Novo A/S
6.98%
JPMorgan Chase & Co
2.01%
See all

Insights on 4D Molecular Therapeutics Inc

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Price Rise

    img

    In the last 1 year, FDMT stock has moved up by 98.6%

  • imgPOSITIVE IMPACT

    Best in 1 Year

    img

    In the last 1 year, FDMT has outperformed top 5 stocks with highest market-cap in its industry

  • imgNO EFFECT

    Against Peers

    img

    In the last 3 years, 4D Molecular Therapeutics, Inc. Common Stock has experienced a drawdown of -55.7%, however Alnylam Pharmaceuticals, Inc. Common Stock resisted the overall trend and outperformed by 40.4%

  • imgNEGATIVE IMPACT

    Revenue Fall

    img

    Revenue is down for the last 2 quarters, 85.09M → 3.04M (in $), with an average decrease of 96.4% per quarter

  • imgNEGATIVE IMPACT

    Profit Down

    img

    Netprofit is down for the last 2 quarters, 19.39M → -68.76M (in $), with an average decrease of 454.5% per quarter

About 4D Molecular Therapeutics Inc

4D Molecular Therapeutics, Inc., a late-stage biotechnology company, engages in the development of adeno-associated virus vectors from its proprietary synthetic vector discovery platform, Therapeutic Vector Evolution in the Netherlands and the United States. The company's lead product candidate is 4D-150 for the treatment of retinal vascular diseases by providing multi-year sustained production of anti-VEGF from the retina with intravitreal injection, as well as for treating wet age-related macular degeneration and diabetic macular edema. It is also developing 4D-710, which is in early-stage study for the treatment of cystic fibrosis; 4D-175 that is in preclinical stage for treating geographic atrophy; and 4D-725, which is in preclinical stage for the treatment of alpha-1 anti-trypsin deficiency lung disease. 4D Molecular Therapeutics, Inc. has collaboration and licensing agreements with Otsuka Pharmaceutical Co., Ltd. The company was founded in 2013 and is headquartered in EmeryVille, California.
Organisation4D Molecular Therapeutics Inc
Headquarters5858 Horton Street, EmeryVille, CA, United States, 94608
IndustryBiotechnology
CEODr. David H. Kirn M.D.
E-voting on sharesClick here to vote

Key Management of 4D Molecular Therapeutics Inc

Name

Title

Dr. David H. Kirn M.D.

Co-Founder, President, CEO & Director

Mr. Kristian Humer M.B.A.

CFO and Principal Financial & Accounting Officer

Dr. Fariborz Kamal Ph.D.

Chief Technical Advisor

Dr. Katy Barglow Ph.D.

Chief Technical Officer

Dr. Scott P. Bizily J.D., Ph.D.

Chief Legal Officer & Corporate Secretary

Dr. An Song Ph.D.

Chief Translational Medicine Advisor

Dr. Noriyuki Kasahara M.D., Ph.D.

Chief Scientific Advisor & Member of Scientific Advisory Board

Dr. John F. Milligan Ph.D.

Executive Chairman

Ms. Theresa Janke

Co-Founder & Chief of Staff

Julian Pei

Head of Investor Relations & Corporate Finance

FAQs

What is 4D Molecular Therapeutics Inc share price today?

4D Molecular Therapeutics Inc share price today is $8.55 as on . 4D Molecular Therapeutics Inc share today touched a day high of $8.81 and a low of $8.41.

What is the 52 week high and 52 week low for 4D Molecular Therapeutics Inc share?

4D Molecular Therapeutics Inc share touched a 52 week high of $12.34 on and a 52 week low of $3.68 on . 4D Molecular Therapeutics Inc stock price today i.e. is trending at $8.55,which is 30.71% down from its 52 week high and 132.34% up from its 52 week low.

What is 4D Molecular Therapeutics Inc's market capitalisation today?

4D Molecular Therapeutics Inc market capitalisation is $0.00T as on .

How to invest in 4D Molecular Therapeutics Inc Stock (FDMT) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for 4D Molecular Therapeutics Inc on INDmoney app. Click on Buy button. You can invest as low as $1.5 in 4D Molecular Therapeutics Inc Shares that will get you 0.1754 shares as per 4D Molecular Therapeutics Inc share price of $8.55 per share as on June 8, 2026 at 9:07 pm IST.

What is the minimum amount required to buy 4D Molecular Therapeutics Inc Stock (FDMT) from India?

Indian investors can start investing in 4D Molecular Therapeutics Inc (FDMT) shares with as little as ₹95.7075 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹957.07 in 4D Molecular Therapeutics Inc stock (as per the Rupee-Dollar exchange rate as on ). Based on 4D Molecular Therapeutics Inc share’s latest price of $8.55 as on June 8, 2026 at 9:07 pm IST, you will get 1.1696 shares of 4D Molecular Therapeutics Inc. Learn more about fractional shares .

What are the returns that 4D Molecular Therapeutics Inc has given to Indian investors in the last 5 years?

4D Molecular Therapeutics Inc stock has given -67.65% share price returns and 30.15% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?